LOS ANGELES CAPITAL MANAGEMENT LLC

Position in CLDX — Celldex Therapeutics, Inc.

CIK 1177206 LOS ANGELES, CA

Position in CLDX

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$9,749

+$1,439 QoQ

Shares Held

262

0.0% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#218

of 252 holders

Holding Since

Jun 2023

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. CLDX ranks #140 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$9,749	262	0.0%	Shares	Sole	2026-08-13
2026-03-31	$8,310	262	0.0%	Shares	Sole	2026-05-08
2025-12-31	$7,115	262	-98.3%	Shares	Sole	2026-02-11
2024-12-31	$389,688	15,421	+128.9%	Shares	Sole	2025-02-04
2024-09-30	$229,024	6,738	-8.6%	Shares	Sole	2024-11-04
2024-06-30	$272,800	7,371	+9.5%	Shares	Sole	2024-08-05
2024-03-31	$282,584	6,733	-58.1%	Shares	Sole	2024-04-05
2023-09-30	$442,576	16,082	+0.3%	Shares	Sole	2023-11-06
2023-06-30	$543,762	16,026	—	Shares	Sole	2023-08-03
No filing history on record for this holder in this stock.